

compartmentation and electrolytes of cat cerebral cortex *in vitro*. I. Swelling and solute distribution in mature cerebral cortex. *J. Neurochem.*, **13**, 1071–1097.

ROBERTS, FIONA (1976). The *in vivo* uptake of ³H-GABA into the dorsal surface of rat medulla. *Proc. Eur. Soc. Neurochem.*, **13P**.

ROBERTS, P.J. (1974). The release of amino acids with

proposed neurotransmitter function from the cuneate and gracile nuclei of the rat *in vivo*. *Brain Res.*, **67**, 419–425.

SRINIVASAN, V., NEAL, M.J. & MITCHELL, J.F. (1969). The effect of electrical stimulation and high potassium concentration on the efflux of ³H-γ-aminobutyric acid from brain slices. *J. Neurochem.*, **16**, 1235–1244.

t-Butyl bicyclo phosphate: a convulsant and GABA antagonist more potent than bicuculline

N.G. BOWERY, J.F. COLLINS, R.G. HILL & S. PEARSON

Departments of Pharmacology, St. Thomas's Hospital Medical School London SE1 7EH and University of Bristol Medical School BS8 1TD, and Department of Chemistry City of London Polytechnic, Jewry Street, London EC3

Bicuculline is now widely accepted as a selective GABA antagonist (Curtis & Johnston, 1974) and is at present the most potent on mammalian systems. We previously studied a series of convulsant compounds of the formula 4(R)-1-phospha 2,6,7 trioxabicyclo (2,2,2) octane-1-oxide (R-PTBO where R = alkyl group) and showed that the isopropyl derivative (IPTBO) was equipotent with bicuculline as a GABA antagonist (Bowery, Collins & Hill, 1967a; Bowery, Collins, Hill & Pearson, 1976b). Other alkyl substituted PTBO derivatives have now been studied, n-propyl (n-ProPTBO), n-butyl (nBPTBO), s-butyl (s-BPTBO), t-butyl (t-BPTBO), methyl (MPTBO) and pentyl

(PPTBO), and our results indicate that the t-BPTBO derivative is more potent than bicuculline.

Convulsant potency was determined by intravenous injection in adult mice. GABA antagonism was assessed from the depression of depolarizing responses to GABA in the frog spinal cord and rat superior cervical ganglion as described previously (Bowery *et al.*, 1976b). Relative potencies were obtained by comparison with IPTBO and bicuculline at concentrations required to inhibit responses to fixed submaximal doses of GABA by 50%. This method was adopted since previous experiments have indicated that the PTBO derivatives appear to act non-competitively (Bowery *et al.*, 1976a).

All the derivatives had similar actions to those already described for IPTBO (Bowery *et al.*, 1976a, 1976b). Convulsions consisted of rapid clonic jerks leading to tonic extension with larger doses. CD₁₀₀ values are shown in Table 1. Responses to GABA (0.5–4 mM) in the frog spinal cord were readily antagonized by the PTBO derivatives whereas response to glycine and glutamate were unaffected. The derivatives also antagonized the depolarizing action of GABA (1–300 μM) in the superior cervical ganglion without affecting responses to carbachol. The relative molar potencies are shown in Table 1.

Table 1

Compound	CD ₁₀₀ μg/kg* i.v. mice	Relative molar potency as GABA antagonist†	
		Frog spinal cord	Rat superior cervical ganglion
t-BPTBO	25	3.5	4.2
IPTBO	140	1.0	1.0
s-BPTBO	100	0.47	1.0
n-ProPTBO	300	0.2	0.2
n-BPTBO	800	0.08	0.07
PPTBO	1200	<0.01	<0.01
MPTBO	>4000	—	<0.01
Bicuculline	200	0.5‡	1.0‡

* Mean values each determined from 8 groups of 4 mice.

† Determined by comparison with IPTBO within the same experiment. Mean values from 2–6 experiments for each compound.

‡ Bicuculline methochloride.

t-BPTBO was the most potent antagonist and convulsant and was approximately four times more potent than bicuculline. The reasonably close agreement between the CD_{100} values and the molar potencies as antagonists lends further support to the suggestion that the convulsant properties of the PTBO derivatives may be due to antagonism of the actions of synaptically-released GABA (Bowery *et al.*, 1976b).

We wish to thank Dr T.D. Inch for preparing t-BPTBO.

References

- BOWERY, N.G., COLLINS, J.F. & HILL, R.G. (1976a). Bicyclic phosphorus esters that are potent convulsants and GABA antagonists. *Nature, Lond.*, **261**, 601–603.
- BOWERY, N.G., COLLINS, J.F., HILL, R.G. & PEARSON, S. (1976b). GABA antagonism as a possible basis for the convulsant action of a series of bicyclic phosphorus esters. *Br. J. Pharmac.*, **57**, 435–436P.
- CURTIS, D.R. & JOHNSTON, G.A.R. (1974). Amino acid transmitters in the mammalian central nervous system. *Ergebn. Physiol.*, **69**, 97–188.

Influencing morphine self-administration in dependent rats

R. KUMAR, L. MUMFORD & A.R. TEIXEIRA

Institute of Psychiatry, University of London SE5 8AF

Naive rats do not normally drink solutions of morphine, possibly because they are bitter tasting (to man) and possibly because of the post-ingestional effects of the drug. Rats can, however, learn to prefer such solutions (morphine HCl 0.5 mg/ml) to plain water if they are repeatedly 'forced' to drink them in order to relieve thirst. Once such preferences have been acquired, they are relatively stable and persistent and provide a useful animal model of dependence on morphine (Stolerman & Kumar, 1970). There are a number of conceptually distinct ways of trying to change patterns of behaviour that are maintained by pharmacological reinforcers. We report some experiments in rats with established preferences for morphine in which different 'treatment' procedures were compared for their ability to reduce or eliminate morphine-seeking behaviour.

Dependent rats ($n=9$) which received injections of saline 2 h before their daily choice tests continued to ingest about 60% of their daily fluid intake in the form of morphine solution; this corresponded to a daily dose of approximately 20 mg/kg. Other rats ($n=10$) were injected with morphine HCl (30 mg/kg), 2 h prior to their choice tests for 12 days and this treatment initially reduced the proportion of the daily fluid intake consumed as morphine solution from 63% to 43% ($P<0.005$). Increasing the daily doses of injected morphine up to 120 mg/kg day did not further reduce the proportional intake of the drug.

Rats ($n=10$) treated with naloxone (initially naloxone HCl 1 mg kg^{-1} day $^{-1}$ for 12 days, then

increasing up to 8 mg kg^{-1} day $^{-1}$) 30 min before choice trials showed little change in their patterns of morphine consumption. It is possible that naltrexone, which is also a relatively 'pure' opioid antagonist but with more prolonged actions, might have altered morphine intake. However, both morphine and naloxone were clearly effective in the range of doses used since they inhibited normal growth—the linear trends for the drugged rats' body weights differed significantly from the saline-injected group ($P<0.01$). Thus, other important factors, apart from the need to relieve withdrawal symptoms or to obtain primary positive reinforcement, must be involved in sustaining morphine preferences.

When saccharin sodium (0.5 mg/ml) was added to the usual morphine solution and this novel taste was associated with an aversive state, naloxone-precipitated abstinence from morphine (cf. Pilcher & Stolerman, 1976), dependent rats ($n=10$) subsequently markedly avoided this mixture in preference tests; they took about 5% of their fluid as drug solution. This aversion was long lasting and it did not generalize either to solutions of morphine alone ($P<0.005$) or to saccharin alone ($P<0.01$). Control (non-averted) subjects showed clear preferences for morphine + saccharin solutions and the preference for this now familiar taste was resistant to the aversion procedure.

References

- PILCHER, C.W.T. & STOLERMAN, I.P. (1976). Conditioned flavor aversions for assessing precipitated morphine abstinence in rats. *Pharmac. Biochem. Behav.*, **4**, 159–163.
- STOLERMAN, I.P. & KUMAR, R. (1970). Preferences for morphine in rats: validation of an experimental model of dependence. *Psychopharmacologica (Berl.)*, **17**, 137–150.